Mangoceuticals

Mangoceuticals, Inc. offers a telemedicine service specializing in the treatment of erectile dysfunction. Mangoceuticals' target market covers about one-third of the male population.

Through the recently launched web service MangoRX, patients can contact medical specialists, receive referrals for tests, prescriptions for medications, and immediately order the required drugs.

To date, Mangoceuticals has obtained a license for an online pharmacy and is preparing to commercially launch its own drug called Mango ED. It includes components already approved by the U.S. Food and Drug Administration (FDA). Therefore, Mangoceuticals plans to sell the drug in individual doses not as a medication, but under a simpler regulatory scheme that pertains to dietary supplements and cosmetics. This approach reduces costs, but competitors can use the recipe.

Mangoceuticals plans to use the funds from the IPO to finance the marketing of the Mango ED drug and launch sales in the next quarter, following the IPO.
_______________________________

Number of employees: 2-10
______________________________

Headquarters location: Dallas, Texas, USA.